ClinicalTrials.gg
RecruitingNCT07548710Updated Jul 30, 2026

Study of SA+X in the Treatment of Newly Diagnosed AML

A Phase 2 interventional study of Anthracycline and Ivosidenib in Acute Myeloid Leukemia, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Sponsored by Ruijin Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
205
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Planned enrollment
26th of 211
205 · median 50
Started
2026
with 25 others
Phase 2
105 of 214
40 open now
Primary completion
2027-05
later than 35 of 90 live
Registered
205th of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 26th largest by planned enrollment of the 211 interventional ones that give a count, is one of 26 that started in 2026, is one of 105 in phase 2, reaches primary completion later than 35 of the 90 other live ones, and was the 205th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

66 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This is a phase II, open-label, multi-center study evaluating the efficacy and safety of sonrotoclax (SA) in combination with azacitidine (AZA) plus individualized targeted or chemotherapeutic agents in adult participants with newly diagnosed acute myeloid leukemia (AML). Eligible participants will be stratified into different treatment arms based on genetic background (FLT3/IDH1 mutation status) and fitness for intensive chemotherapy. All participants will receive sonrotoclax with dose escalation from 20 mg/day to 320 mg/day, followed by maintenance dosing, which may be temporarily held by the investigator from Day 14 to Day 28 of each 28-day cycle based on the participant's condition, combined with azacitidine 75 mg/m²/day intravenously on Days 1-7. For participants fit for intensive chemotherapy, additional anthracycline (daunorubicin 60 mg/m²/day or idarubicin 10 mg/m²/day on Days 1-3) will be administered. For participants with FLT3 mutations, gilteritinib 80 mg once daily on Days 1-14 will be added; for those with IDH1 mutations, ivosidenib 500 mg once daily on Days 1-28 will be added.

03

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Newly Diagnosed Adult Acute Myeloid Leukemia
  • Sonrotoclax
  • Azacitidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Newly diagnosed AML confirmed by bone marrow morphology and immunophenotyping (5th edition WHO diagnostic criteria)
  • Subjects with APL excluded according to fusion gene and chromosome results
  • performance status 0-3
  • Age ≥ 18 years
  • White blood cell count must be \< 25 × 10⁹/L at the start of study treatment (can be reduced by leukapheresis and/or hydroxyurea)
  • Subjects must have adequate organ function, defined as follows: Serum (AST) and alanine aminotransferase (ALT) ≤ 3 × (ULN), unless elevated due to leukemic organ involvement; serum total \< 3 × ULN; higher levels are acceptable if attributable to ineffective erythropoiesis, leukemic organ involvement, or Gilbert syndrome; serum creatinine \< 3 × ULN, or estimated ≥ 30 mL/min by Cockcroft-Gault formula
  • Written obtained from the subject or legal representative

Exclusion criteria

Exclusion Criteria:

  • FAB classification as M3, or molecularly confirmed APL
  • / relapsed subjects
  • Subjects with a history of myeloproliferative neoplasms (MPN);
  • Subjects with a history of chronic myeloid leukemia (CML);
  • Subjects with mixed phenotype acute leukemia (MPAL);
  • Documented central nervous system leukemia;
  • or allergy to any of the study drugs;
  • Physical conditions or organ system dysfunction that impairs the ability to swallow capsules or tablets, or significantly affects gastrointestinal function and/or absorption (including malabsorption syndrome, small bowel resection, or uncontrolled inflammatory bowel disease);
  • Cardiac conditions meeting any of the following:a) Long syndrome or QTc interval > 480 ms;b) Second- or third-degree atrioventricular block; severe, uncontrolled arrhythmia requiring medical treatment;c) History of myocardial infarction, unstable angina, severe unstable ventricular arrhythmia, or any other treatable arrhythmia, pericardial disease within 6 months prior to enrollment; or electrocardiographic evidence of acute ischemia or active conduction system abnormalities;
  • Current concurrent other than adequately controlled non-melanoma skin basal cell carcinoma, in situ breast/cervical carcinoma, or other malignancies adequately controlled without treatment for more than 6 months;
  • Significantly abnormal liver or renal function (serum , , ALT, or serum creatinine > 3 × ; excluding those deemed by the investigator to be related to AML);
  • Subjects who have received previous anti-AML therapies other than hydroxyurea for cytoreduction, including but not limited to BCL-2, FLT3, IDH1 inhibitors, or other agents;
  • Coagulopathy unrelated to AML;
  • infection, syphilis infection, infection, or active infection (HBsAg positive; or HBsAg negative / HBcAb positive with HBV DNA > 1.0 × ULN); Patients with previously documented such infections who have achieved undetectable viral load or sustained viral load reduction after treatment may be enrolled at the investigator's discretion;
  • Other uncontrolled active infection (as judged by the investigator);
  • Pregnant or breastfeeding women;
  • Unable to understand or comply with the study protocol;
  • Participation in other relevant clinical studies within 30 days (excluding diagnostic studies);
  • Subjects deemed inappropriate for study participation by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
205 participants (estimated)

Study arms

  • Experimental
    SA+Anthracycline

    Drug: Anthracycline · Drug: Sonrotoclax · Drug: Azacitidine (AZA)

  • Experimental
    SA+FLT3 inhibitor

    For patients harboring FLT3-TKD mutations, gilteritinib is the preferred agent; for those with FLT3-ITD mutations, either gilteritinib or quizartinib is a valid treatment option.

    Drug: Gilteritinib · Drug: Sonrotoclax · Drug: Azacitidine (AZA) · Drug: Quizartinib Dihydrochloride

  • Experimental
    SA+IDH1 inhibitor

    Drug: Ivosidenib · Drug: Sonrotoclax · Drug: Azacitidine (AZA)

  • Experimental
    SA

    Drug: Sonrotoclax · Drug: Azacitidine (AZA)

Interventions

  • DrugAnthracyclinesStudies of AnthracyclinesAnthracyclines pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For FLT3/IDH1 wild-type participants who are eligible for chemotherapy, Anthracycline: Daunorubicin (DNR) 45 mg/m² per day on Days 1-3, or Idarubicin (IDA) 6 mg/m² per day on Days 1-3.

  • For IDH1 mutant participants, IDH1 inhibitor (IDH1i): Ivosidenib 500 mg once daily on Days 1-28.

  • For FLT3 mutant participants, FLT3 inhibitor (FLT3i): Gilteritinib 80 mg once daily on Days 1-14.

  • For all the participants who are eligible for this trial, Sonrotoclax (SON): 20 mg/day on Day 1, 40 mg/day on Day 2, 80 mg/day on Day 3, 160 mg/day on Day 4, and 320 mg/day on Days 5-28 of a 28-day cycle; the administration of SON may be temporarily held by the investigator from Day 14 to Day 28 based on the participant's condition.

  • DrugAzacitidineStudies of AzacitidineAzacitidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For all the participants who are eligible for this trial, Azacitidine (AZA): 75 mg/m² per day on Days 1-7.

  • DrugQuizartinibStudies of QuizartinibQuizartinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    For FLT3-ITD mutant participants, FLT3 inhibitor (FLT3i): Quizartinib Dihydrochloride 40 mg once daily on Days 1-14.

06

What researchers measure

Primary outcomes

  1. Composite Complete Remission

    Time frame: At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

Secondary outcomes

  1. Minimal Residual Disease (MRD) Negativity Rate

    Time frame: At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

  2. Overall Response Rate

    Time frame: At the end of 2 cycles of induction therapy with the SA+X regimen (each cycle is 28 days); at the end of 4 cycles of induction therapy with the SA regimen (each cycle is 28 days).

  3. Overall Survival

    Time frame: Time from enrollment to all-cause death within 3 years

  4. Event-free Survival

    Time frame: Time from enrollment to treatment failure, relapse, or death from any cause within 3 years

  5. Adverse Events

    According to the CTCAE Version 6.0 criteria

    Time frame: From the start of induction to 30 days after the completion of treatment

  6. Time to neutrophil and platelet recovery

    Time frame: From the start of induction to 30 days after the completion of treatment

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2027, 12 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 12 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 23, 2026
StartActual
May 1, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
Dec 21, 2028
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07548710
Lead sponsor
Ruijin Hospital
Collaborators
Shanghai Fengxian District Central Hospital, Chinese People's Liberation Army No 455 Hospital, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai Tong Ren Hospital, Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai, Shanghai Jiahui International Hospital, The First Hospital of Jilin University, Huadong Hospital, The First People's Hospital of Yunnan, Shanghai 7th People's Hospital
Responsible party
Shen yang (Chief physician, Ruijin Hospital) — Principal investigator
First posted
Apr 23, 2026
Start date
May 1, 2026
Primary completion
May 31, 2027 (estimated)
Completion
Dec 21, 2028 (estimated)
Last update
Jul 30, 2026

Study contacts

Yang Shen
Contact
sy_clinicaltrial@163.com
+86-021-64370045

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sonrotoclax · Azacitidine

Start the discussion